Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Euvolemic or hypervolemic (edematous) based on clinical presentation~* Serum sodium between 115 and 130mEq/L at baseline~Exclusion Criteria:~* Clinical presentation of volume depletion or dehydration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regimen 1 Conivaptan QD (Type: EXPERIMENTAL): 20 mg conivaptan once a day
- Regimen 2 Conivaptan BID (Type: EXPERIMENTAL): 20 mg conivaptan two times a day
- Regimen 3 Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).